Pain, General | March 8, 2016 | Author: The Super Pharmacist
Ankylosing spondylitis is a condition that affects the spine as well as the joints between this structure and the pelvis. It is a chronic inflammation of these bones. Ankylosing spondylitis may be associated with new bone growth in and between spinal joints, resulting in their fusion into one structure over time. This is known as ankylosis, or the amalgamation of several bones into one. Ankylosis of the spine may result in characteristic deformities, including 'bamboo spine'. It is associated with the release of 'pro-inflammatory' molecules such as TNFalpha.
The symptoms of ankylosing spondylitis may include:
Some research indicates that ankylosing spondylitis may be associated with the increased risk of hip disease. A study of 265 patients found that sacroiliitis (or the inflammation of joints between the spine and pelvis), delays in diagnosis, early onset and functional status in ankylosing spondylitis were associated with severe hip disease.
Ankylosing spondylitis may be associated with a slight increase in the risk of cardiovascular disorders. A study comparing forty patients to an equal number of healthy controls without cardiovascular risk factors found that the risk markers carotid intima-media thickness (CIMT) and epicardial adipose tissue thickness (EAT), were significantly greater in the patient group in comparison to controls.
Other conditions such as uveitis, inflammatory bowel disease and psoriasis are prevalent among patients with ankylosing spondylitis.
The exact cause of ankylosing spondylitis has not been defined. It is associated with some risk factors, or variables that influence the probability of the development of this condition.
These may include:
Immune system activity: A study including 55 patients with mild to severe ankylosing spondylitis and 20 matched healthy individuals found differences in the proportions of various immune-system cells between these groups.
The patients had significantly increased numbers of T helper cells (Th1 and Th17 subtypes) compared to the controls. This may explain the presence of pro-inflammatory molecules seen in the condition.
Ankylosing spondylitis has also been found to be associated with other components of the immune system, including the major histocompatibility complex (MHC) and the 'master immune control' molecule NFkappaB. There is also some evidence that suggests that ankylosing spondylitis may be an autoimmune condition.
Click Here For Article
Genetic factors: The gene HLA-B27 is thought to play a role in the development of ankylosing spondylitis. The development of this condition is also associated with a family history of similar conditions (i.e. arthritis of the spine).
Trauma: Ankylosing spondylitis may be associated with musculoskeletal trauma in some cases.
Infection or inflammation in other tissues: A study of 58 children with ankylosing spondylitis found that the onset of the condition was associated with fever, dysentery or urethritis in up to 41% of cases. A history of conditions such as conjunctivitis and iritis was also associated with the condition.
Male gender: The same study found that the number of boys with ankylosing spondylitis was double the number of girls with the condition. Studies in other populations have found that the ratio of male to female patients is closer to 4:1.
Vitamin D deficiency: A review of eight trials including 533 patients and 478 matched healthy controls indicated that increased serum vitamin D was significantly associated with the decreased risk of ankylosing spondylitis.
There are several treatment options for ankylosing spondylitis, including:
Infliximab is an anti-TNFalpha antibody, or a protein that locates and binds to TNFalpha to prevent its function in the increase of inflammation in conditions such as ankylosing spondylitis. A pilot study administered 5mg/kg infliximab to eleven patients with active ankylosing spondylitis at three points, two or four weeks apart. Nine patients experienced an improvement in pain scores, functional status and activity levels as a result. This lasted for six weeks after the last administration for eight patients. This indicates the potential of TNFalpha antibody therapy in the treatment of ankylosing spondylitis. However, one patient in this study withdrew due to adverse effects after the first treatment session.
Another anti-TNFalpha antibody, adalimumab, is also currently in use as a treatment for ankylosing spondylitis. This is associated with significant responses and improvements in disease rating scales.
Other anti-TNFalpha antibodies used in the treatment of this condition include:
Conditioning and training may have beneficial effects in conditions such as ankylosing spondylitis, by strengthening the muscles, ligaments and tendons that surround and support the spine. This may lead to improvements in functional status and reductions in pain. A review of 18 high-quality studies on exercise in ankylosing spondylitis management found significant positive effects on disease intensity, patient mobility and functional status compared to normal activity.
Non-steroidal anti-inflammatory drugs are associated with the significant reduction of inflammation, and are often used in the treatment of ankylosing spondylitis. They may be used continuously or as needed in response to pain onset. A review of studies on NSAIDs in ankylosing spondylitis treatment found that there was no significant difference in symptom control between these strategies. Four studies showed a decrease in disease progression as a result of continuous NSAID therapy. NSAIDs are associated with increased risks of adverse effects with regular intake. However, a study of ankylosing spondylitis treatment with celecoxib found no significant differences between the incidence of side effects between patients who used the drug continuously and those who used it at need.
Osteotomies are surgical procedures to correct severe spinal deformity, if necessary. Osteotomy using up-to-date techniques and applications (e.g. pedicle subtraction) may result in significant correction of kyphosis and the restoration of normal activities such as walking fully upright. Other forms of surgery required in severe advanced ankylosing spondylitis may include total hip replacement.
Click Here For Article on Natural Therapies that may Help Ankylosing spondylitis
Wang C, Liao Q, Hu Y, Zhong DA. T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis. Exp Ther Med. 2015;9(1):250-256.
Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000;43(6):1346-1352.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-368.
Liu C, Song K, Zhang Y, et al. Changes of the abdomen in patients with ankylosing spondylitis kyphosis. Spine (Phila Pa 1976). 2015;40(1):E43-48.
Calvo-Gutierrez J, Garrido-Castro JL, Gil-Cabezas J, et al. Is spinal mobility in patients with spondylitis determined by age, structural damage, and inflammation? Arthritis Care Res (Hoboken). 2015;67(1):74-79.
Zhao J, Zheng W, Zhang C, Li J, Liu D, Xu W. Radiographic hip involvement in ankylosing spondylitis: factors associated with severe hip diseases. J Rheumatol. 2015;42(1):106-110.
Malinowski KP, Kawalec P. The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2015:1-16.
Resorlu H, Akbal A, Resorlu M, et al. Epicardial adipose tissue thickness in patients with ankylosing spondylitis. Clin Rheumatol. 2015;34(2):295-299.
Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65-73.
Smith JA. Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep. 2015;15(1):489.
Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997;40(10):1823-1828.
Jacobs JC, Berdon WE, Johnston AD. HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr. 1982;100(4):521-528.
Shahlaee A, Mahmoudi M, Nicknam MH, Farhadi E, Fallahi S, Jamshidi AR. Gender differences in Iranian patients with ankylosing spondylitis. Clin Rheumatol. 2015;34(2):285-293.
Cai G, Wang L, Fan D, et al. Vitamin D in ankylosing spondylitis: review and meta-analysis. Clin Chim Acta. 2015;438:316-322.
Tan S, Yao J, Flynn JA, Yao L, Ward MM. Quantitative syndesmophyte measurement in ankylosing spondylitis using CT: longitudinal validity and sensitivity to change over 2 years. Ann Rheum Dis. 2015;74(2):437-443.
Kneepkens EL, Wei JC-C, Nurmohamed MT, et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis. 2015;74(2):396-401.
Migliore A, Bizzi E, Bernardi M, Picchianti Diamanti A, Laganà B, Petrella L. Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis. Clin Drug Investig. 2015;35(1):23-29.
Martins NA, Furtado GE, Campos MJ, Leitão JC, Filaire E, Ferreira JP. Exercise and ankylosing spondylitis with New York modified criteria: a systematic review of controlled trials with meta-analysis. Acta Reumatol Port. 2014.
Guellec D, Nocturne G, Tatar Z, et al. Should non-steroidal anti-inflammatory drugs be used continuously in ankylosing spondylitis? Joint Bone Spine. 2014;81(4):308-312.
Xu H, Zhang Y, Zhao Y, Zhang X, Xiao S, Wang Y. Radiologic and clinical outcomes comparison between single- and two-level pedicle subtraction osteotomies in correcting ankylosing spondylitis kyphosis. Spine J. 2015;15(2):290-297.
Zheng GQ, Zhang YG, Chen JY, Wang Y. Decision making regarding spinal osteotomy and total hip replacement for ankylosing spondylitis: experience with 28 patients. Bone Joint J. 2014;96-B(3):360-365.